Assiut university
Asyut, Asyut Governorate, 71111, Egypt
NCT Number: NCT02580344
The Copper intrauterine device is the most common method of reversible contraception worldwide. Abnormal uterine bleeding and pain are the most common medical indications for the discontinuation of the intrauterine device.
Excessive prostaglandin release in the endometrial cavity appears to play an important role in both bleeding and pain related to copper intrauterine devices.There are many types of prostaglandin metabolites that present in the endometrium one of them is prostacyclin which causes vasodilatation and inhibits platelet aggregation. Another one is thromboxane which has two types; A2 which is active and rapidly converted into B2, which is inactive. Thromboxane causes vasoconstriction and blood clotting.
Non-steroidal anti-inflammatory drugs (NSAIDs) are prostaglandin synthetase inhibitors acting by decreasing production of endometrial prostaglandins; they can improve both heavy uterine bleeding and pain. Since its discovery; several drugs in NSAIDs class have been used to treat heavy uterine bleeding and pain associated with copper intrauterine device use such as mefenamic acid, ibuprofen and naproxen.
The most recent systematic review found NSAIDs is the most widely studied drugs for reduction of the menstrual blood and pain associated with copper intrauterine device. The Cochrane Review also found that NSAIDs are the most effective treatment to reduce the bleeding with copper intrauterine device use.
Looking for future studies?
Notify Me20 year–45 year
Female
Interventional
Phase 2
Asyut, Asyut Governorate, 71111, Egypt
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The women will receive 400mg ibuprofen 3 times per day from the first day of the cycle for 5 days
Time frame: 3 months
by menstrual diary
Time frame: 3 months
Assiut University
Other
Action of Ibuprofen on IUD-associated Heavy Menstrual Bleeding
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06557499
Contraception
Berkeley, California, United States
View Trial DetailsNCT07326007
Contraception
Giza, Egypt
View Trial DetailsNCT05732142
Contraception, Gender Equity
La Jolla, California, United States
View Trial DetailsNCT03127722
Contraception
Chandler, Arizona, United States
View Trial Details